Trial
NCT05314517
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Kinevant Sciences GmbH
Collaborators
—
Condition
Sarcoidosis, Pulmonary
Intervention
Namilumab
Why stopped
Sponsor Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-12